Carboxypeptidase B-1 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Carboxypeptidase B-1 (CPB1, UniProt P15086), expressed in HEK293 cells. Suited for peptidase activity assays, inhibitor IC50 determination, and antibody validation as a positive control standard.
Expression system
HEK293
Cat. #
REC-CarboxypeptidaseB1

In stock

SKU
REC-CarboxypeptidaseB1
$498.00

Target Overview

Carboxypeptidase B-1 (CPB1; UniProt P15086) is a zinc-dependent metallocarboxypeptidase (EC 3.4.17.2) that selectively cleaves basic C-terminal residues — arginine and lysine — from peptide substrates. The full-length human CPB1 precursor comprises 417 amino acids and is secreted as an inactive zymogen (procarboxypeptidase B); activation occurs via proteolytic removal of the N-terminal propeptide. The mature enzyme is expressed predominantly in the exocrine pancreas, where it participates in dietary protein digestion. This recombinant form is produced in HEK293 mammalian cells, providing post-translational modifications and folding characteristics consistent with the native human protein — an advantage over prokaryotic expression systems when enzymatic activity or conformation-sensitive antibody binding is the primary research objective. Researchers use this recombinant in several in vitro contexts: (1) peptidase activity assays using chromogenic or fluorogenic substrates bearing C-terminal Arg or Lys residues; (2) inhibitor screening and IC50 determination against candidate small molecules or natural inhibitors such as potato carboxypeptidase inhibitor; (3) as a well-characterised positive control antigen for Western blot and IHC validation of anti-CPB1 antibodies. Researchers validating antibody performance can pair this recombinant directly with the matched Triple Point Biologics anti-CPB1 antibody (SKU: RP-CarboxypeptidaseB1), which has been validated for Western blot against human samples. Beyond pancreatic physiology, CPB1 has attracted research interest in the context of biomarker studies for exocrine pancreatic function and in transcriptomic and metabolomic profiling studies examining digestive enzyme expression across tissue types and developmental stages.

Background

CPB1 encodes a member of the M14 family of zinc carboxypeptidases, enzymes characterised by a catalytic zinc ion coordinated within a conserved α/β-hydrolase fold. In the pancreatic acinar cell, CPB1 is synthesised and stored as procarboxypeptidase B, a zymogen co-secreted into the duodenum alongside other pancreatic proteases. Tryptic cleavage of the activation segment yields the catalytically competent enzyme, which processes dietary peptides by removing C-terminal basic residues. This positional specificity distinguishes CPB1 from carboxypeptidase A isoforms, which preferentially release hydrophobic C-terminal residues. In published basic research, CPB1 expression has been catalogued across a range of transcriptomic datasets. A 2025 study by Li Z et al. (PMID 40596826) used integrated transcriptome and metabolome analyses to characterise small intestinal biology in weaning bats (*Vespertilio sinensis*), identifying CPB1 among differentially expressed digestive enzyme transcripts — illustrating how the gene serves as a marker of exocrine digestive function in comparative physiology work. Separately, Sheng Z et al. (PMID 39982642) demonstrated that CPB1 expression in lens epithelial cells is regulated at the mRNA modification level: METTL3-mediated m6A methylation modulates transcription factor BACH2 occupancy, thereby controlling CPB1 levels and influencing apoptosis and oxidative stress responses in that cellular context. This finding positions CPB1 as a research target for understanding the intersection of epitranscriptomic regulation and cell stress biology. CPB1 has additionally appeared in cancer-associated transcriptomic profiling studies. Its expression has been noted in analyses of gastric cancer and breast cancer molecular subtypes, where it has been identified as part of broader gene-expression signatures rather than as a characterised driver — making it a candidate marker for further mechanistic investigation in those research contexts. For researchers working on pancreatic exocrine biology, CPB1 enzyme preparations are used to establish kinetic parameters (Km, kcat, kcat/Km) against defined peptide substrates and to benchmark inhibitor potency. Because the propeptide segment itself acts as a reversible inhibitor of the mature enzyme, propeptide-based inhibitor studies represent another established research application. The recombinant HEK293-expressed protein described here provides a defined, human-sequence source material for these experimental approaches. Triple Point Biologics has produced validated proteinase and inhibitor-related antibody reagents since 1994. Researchers requiring complementary immunological tools for CPB1 detection can cross-reference the matched anti-CPB1 antibody (SKU: RP-CarboxypeptidaseB1), validated for Western blot in human samples.

Applications

  • Peptidase activity assay using fluorogenic substrates with C-terminal Arg or Lys (e.g., hippuryl-Arg or dansyl-Ala-Arg)
  • Inhibitor IC50 determination against small-molecule or peptide-based carboxypeptidase B inhibitors
  • Kinetic characterisation (Km, kcat, kcat/Km) against defined chromogenic peptide substrates
  • Antibody validation positive control for Western blot — pairs with Triple Point anti-CPB1 antibody (SKU: RP-CarboxypeptidaseB1)
  • Antibody validation positive control for IHC — pairs with matched anti-CPB1 antibody (SKU: RP-CarboxypeptidaseB1)
  • Propeptide–enzyme interaction studies and propeptide-based inhibitor benchmarking
  • Recombinant antigen for ELISA standard curve construction or sandwich assay development
  • Substrate specificity profiling by LC-MS/MS to map C-terminal cleavage preferences across peptide libraries

References

  1. Sheng Z et al. METTL3 mediates CPB1 expression by regulating transcription factor BACH2 to promote apoptosis and oxidative stress of lens epithelial cells. J Bioenerg Biomembr. 2025. doi:10.1007/s10863-025-10054-1. PMID: 39982642
  2. Li Z et al. Integrated transcriptome and metabolome analyses unraveled critical roles of small intestine during the weaning period of Vespertilio sinensis. BMC Genomics. 2025. doi:10.1186/s12864-025-11784-7. PMID: 40596826
  3. Paulino PJIV et al. Identification of high-risk signatures and therapeutic targets through molecular characterization and immune profiling of TP53-mutant breast cancer. J Genet Eng Biotechnol. 2025. doi:10.1016/j.jgeb.2025.100574. PMID: 41386839
  4. Guo R et al. Unveiling the mechanistic links between plasticizers and gastric cancer via network toxicology and molecular docking approaches. BMC Pharmacol Toxicol. 2025. doi:10.1186/s40360-025-01057-0. PMID: 41327485
  5. Li M et al. Knockdown of cytochrome P450 1 A (cyp1a) gene suppresses growth and oxygen tolerance in zebrafish. Comp Biochem Physiol A Mol Integr Physiol. 2025. doi:10.1016/j.cbpa.2025.111846. PMID: 40118204

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted (most); lysosome (some)

Frequently Asked Questions

What molecular weight does recombinant Carboxypeptidase B-1 run at on SDS-PAGE?

The mature, active form of human CPB1 (UniProt P15086) spans roughly residues 96–417 after propeptide removal, giving a predicted MW of ~35 kDa. On reducing SDS-PAGE, this recombinant produced in HEK293 cells typically migrates at 37–40 kDa — the slight upward shift from the theoretical value reflects N-linked glycosylation contributed by the mammalian expression system. If you are using this as a Western blot size reference, expect the band at approximately 38 kDa under standard reducing conditions.

Is the recombinant CPB1 supplied as the zymogen or the active mature enzyme?

It is supplied as the active mature enzyme, not the inactive procarboxypeptidase B zymogen. The N-terminal propeptide (approximately residues 1–95 of the 417 aa precursor) has been removed during processing, yielding the catalytically competent form. This matters if you are running activity assays or using the protein as an enzymatically active standard — no additional activation step is required. If your assay specifically requires the proenzyme form, this product is not the appropriate choice.

What substrates does Carboxypeptidase B-1 cleave and which should I use for an activity assay?

CPB1 (EC 3.4.17.2) is a zinc-dependent metallocarboxypeptidase that selectively hydrolyzes basic C-terminal residues — arginine and lysine — from peptide substrates. For in vitro activity assays, the chromogenic substrate hippuryl-L-arginine (Hip-Arg) is the most widely used, monitored by absorbance at 254 nm following hippuric acid release. Fluorogenic alternatives such as Abz-Ala-Arg-OH offer better sensitivity in low-volume formats. CPB1 shows negligible activity toward C-terminal aromatic or aliphatic residues, making substrate selectivity a useful quality check when validating lot activity.

What buffer conditions are optimal for CPB1 activity assays with this recombinant?

CPB1 is a zinc-dependent metallocarboxypeptidase, so the assay buffer must preserve the active-site zinc. The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol with 5 mM CaCl2. For activity assays, dilute into a compatible reaction buffer — 50 mM Tris-HCl pH 7.5 or 25 mM HEPES pH 7.4, 100–150 mM NaCl, 5 mM CaCl2 — and keep pH between 7.2 and 8.0. Avoid EDTA or EGTA; even low micromolar concentrations will chelate the catalytic zinc and abolish activity. DTT at ≤1 mM is generally tolerated.

What starting concentration of recombinant CPB1 should I use for a peptidase activity assay?

A reasonable starting point for a Hip-Arg chromogenic assay is 1–5 nM enzyme in a 100–200 µL reaction volume, with substrate in the 0.1–1 mM range to bracket Km. Adjust enzyme concentration to achieve linear initial-rate conditions — typically 5–10% substrate conversion over the measurement window. For fluorogenic Abz-Ala-Arg assays, 0.5–2 nM is usually sufficient given the higher sensitivity. Always run a no-enzyme blank to account for spontaneous substrate hydrolysis, and equilibrate the reaction mix to 37°C before adding enzyme.

Can I use recombinant CPB1 as a positive control for Western blot with the matched RP-CarboxypeptidaseB1 antibody?

Yes — this is one of the primary use cases for pairing REC-CarboxypeptidaseB1 with RP-CarboxypeptidaseB1. The rabbit polyclonal antibody was raised and validated in the same laboratory against CPB1 protein, ensuring the recombinant is recognized reliably on Western blot. Load 10–50 ng of recombinant CPB1 per lane alongside your cell or tissue lysate. The antibody is validated for Western blot, so you should see a clean band at ~38 kDa. This pairing also serves as an antibody validation positive control when assessing new lots of RP-CarboxypeptidaseB1.

How much recombinant Carboxypeptidase B-1 should I load as a Western blot positive control?

Load 20–50 ng per lane as a starting point when using the matched RP-CarboxypeptidaseB1 antibody (SKU: RP-CarboxypeptidaseB1). At this range, the ~38 kDa band is consistently detectable without saturating the signal or obscuring nearby bands in adjacent lysate lanes. If your secondary antibody or detection system is high-sensitivity (e.g., HRP with femtomolar chemiluminescence substrates), titrate down to 5–10 ng. Dilute the recombinant in 1× SDS loading buffer immediately before use; avoid repeated dilution from the same aliquot to minimize activity and protein loss.

How should I store and handle recombinant CPB1 to maintain activity over time?

Store at −20°C in single-use aliquots. The supplied buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2 — is formulated for freeze-thaw stability, but repeated freeze-thaw cycles will progressively degrade metalloprotease activity due to zinc cofactor dissociation and protein aggregation. Upon first use, thaw one aliquot on ice, take what you need, and discard the remainder rather than refreezing. For short-term working stocks (1–3 days), keep at 4°C. Endotoxin is <0.1 EU/µg by LAL assay, making it suitable for cell-based applications where LPS contamination is a concern.

Validation imagery coming soon

Western blot validation figures for REC-CarboxypeptidaseB1 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →